Thu. 8 Feb 2024, 2:21am ET
Benzinga
News
- Over 40 sites (U.S. and Canada) have agreed to participate in the LEVEL study
- LEVEL is a randomized, controlled Phase 3 trial of 152 patients, and will recruit patients primarily from leading research centers with large PH-HFpEF populations
- Tenax forecasts topline LEVEL data will be available second half of 2025